Ryan Livingston joined the MJH Life Sciences team in March of 2025, shortly after graduating from TCNJ with a bachelor’s degree in English. He enjoys creative writing, reading, and scuba diving. He can be reached at rlivingston@mjhlifesciences.com.

 has evolved significantly in 2025, with the key approvals from the 

 of inclisiran and plozasiran and the major trial advances of olezarsen and enlicitide. 

, hypercholesterolemia, and LDL-C management have all received crucial new preventive or protective measures during the course of the year, providing new resources for historically underserved populations.

Given the amount of critical news from 2025, the editorial team at 

 has collected 13 of the most impactful headlines from the last 12 months, including FDA announcements, critical trial results, and key clinician insights. Catch up on anything you may have missed below.


FDA Approves Inclisiran (Leqvio) Label Update as First-Line Monotherapy in Hypercholesterolemia

On July 31, 2025, inclisiran’s label was updated to allow its use as a first-line monotherapy, along with diet and exercise, to reduce low-density lipoprotein cholesterol (LDL-C) in adults with hypercholesterolemia. Parent company Novartis announced the FDA’s proactive request of the label update, based on the robust LDL-C lowering data for PCSK9-targeting therapies. Prior to the update, inclisiran was required to be used on top of or in combination with statin therapy – the update also revised instances of “primary hyperlipidemia” to “hypercholesterolemia” to enhance focus on LDL-C reduction.


FDA Approves Plozasiran for Adults With Familial Chylomicronemia Syndrome

Plozasiran was approved on November 18, 2025, for the reduction of triglycerides in adult patients with familial chylomicronemia syndrome (FCS). The first-in-class RNA interference therapeutic is designed to reduce the production of apoC-III, a major component of triglyceride-rich lipoproteins and a regulator of triglyceride metabolism. The approval was based on the PALISADE trial, which saw patients receiving plozasiran exhibit an 80% median change in triglycerides from baseline and an 83% decreased risk of acute pancreatitis compared to placebo.


FDA Approves Lerodalcibep-liga (Lerochol) for LDL-C Reduction in Hypercholesterolemia

On December 15, 2025, the FDA approved lerodalcibep-liga, under the brand name Lerochol, as an adjunct to diet and exercise to reduce LDL-C in adults with hypercholesterolemia, including heterozygous familial hypercholesterolemia (HeFH). The novel, small protein-binding, third-generation PCSK9 inhibitor, designed as a once-monthly, single small-volume subcutaneous injections for LDL-C lowering, was approved on the back of the LIBerate program, a series of 5 phase 3 registration studies including 2900 patients.


CORALreef Lipids: Enlicitide Lowers LDL-C as Much as Injectables, With Ann Marie Navar, MD, PhD

The CORALreef Lipids phase 3 trial highlighted the efficacy of an oral, once-daily dose of PCSK9 inhibitor enlicitide in significantly reducing LDL-C compared to placebo in patients with hypercholesterolemia with or at risk of 

atherosclerotic cardiovascular disease (ASCVD)

. The 24-week trial compared enlicitide 20 mg to placebo, displaying an LDL-C reduction of ≤60% in the enlicitide cohort, which was maintained at 52 weeks. Patients also saw a 53% reduction in non-HDL, a 50% reduction in ApoB, and a 28% reduction in Lp(a).


CORE/CORE2: Olezarsen Achieves Primary Endpoint in Severe Hypertriglyceridemia

The phase 3 CORE and CORE2 trials both highlighted olezarsen’s capacity for substantial reductions in fasting triglyceride levels among patients with severe hypertriglyceridemia. The investigative antisense oligonucleotide slows triglyceride clearance by inhibiting lipoprotein lipase activity and the liver’s uptake of triglyceride-rich particles. During the trials, olezarsen demonstrated a placebo-adjusted mean reduction in fasting triglyceride of ≤72% at 6 months, which was sustained for the full 12-month trial period.


VICTORION-Difference: Inclisiran Achieves Primary Endpoint of LDL-C Reduction Versus Placebo

Patients with hypercholesterolemia at high or very high risk of cardiovascular events reached LDL-C goals with inclisiran on top of individually optimized lipid-lowering therapy than with placebo in the VICTORION-Difference trial. The small interfering ribonucleic acid targeting PCSK9 messenger RNA provides a consistent reduction in LDL-C when given twice yearly after initial doses. VICTORION-Difference saw 84.9% of patients in the inclisiran arm achieve guideline-recommended LDL-C goals compared to 31% receiving placebo.


Study Finds Icosapent Ethyl Can Reduce Cardiovascular Risk, Even in Well-Controlled LDL-C

The landmark REDUCE-IT trial further examined icosapent ethyl’s cardiovascular benefits for patients, regardless of their baseline LDL-C levels. The trial was the basis for icosapent ethyl’s 2019 FDA approval for reducing cardiovascular risk as an adjunct to maximally tolerated statin therapy in adults with triglyceride levels ≥150 mg/dL and established cardiovascular disease. This secondary analysis examined a composite endpoint of cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, coronary revascularization, or unstable angina based on baseline LDL-C level.


Obicetrapib Achieves Robust LDL-C Reductions in Phase 3 ASCVD Trials

In the BROADWAY and TANDEM phase 3 trials, once-daily oral obicetrapib substantially reduced LDL-C in patients with ASCVD when used as an adjunct to statins. The BROADWAY trial saw obicetrapib achieve a 33% reduction in LDL-C on top of maximally tolerated lipid-lowering therapies, along with a 21% relative reduction in major adverse cardiovascular events. TANDEM saw a fixed-dose combination of obicetrapib and ezetimibe meet all primary endpoints for LDL-C reduction compared with placebo.


RX Review: Updates and Unmet Needs for Familial Chylomicronemia Syndrome

In the first of a 7-part video series discussing recent changes in therapeutic options for patients with FCS, host Viet Le, DMSc, PA-C, a preventive cardiology PA at Intermountain Health and former president of the Academy of Physician Associates in Cardiology, spoke with Christie Ballantyne, MD, chief of cardiovascular research at Baylor College of Medicine and principle investigator in the PALISADE trial, to highlight the challenges and treatment gaps present in FCS care. However, Ballantyne ultimately marks 2025 as a turning point for FCS, with the approval of plozasiran on November 18 and olezarsen’s approval in late 2024 providing targeted therapies capable of substantially reducing triglycerides.


RX Review: Integrating New Therapies in FCS Treatment Algorithms


In the fourth part of this 7-part series, host Viet Le, DMSc, PA-C, and guest Christie Ballantyne, MD, discuss plozasiran and its newfound role in contemporary FCS management. Ballantyne discusses the mechanism of action of small interfering RNA therapies like plozasiran and how they modulate pathways independent of lipoprotein lipase activity. Additionally, the pair discuss how plozasiran expands treatment options in this historically underserved population.


RX Review: Understanding Plozasiran’s Role in FCS Management


In the fifth episode of this 7-part series, host Viet Le, DMSc, PA-C, and guest Christie Ballantyne, MD, discussed the effect olezarsen and plozasiran have had on treatment algorithms for FCS. While the approvals are groundbreaking, Ballantyne cautions careful attention when implementing the new medications, with particular attention to patient needs and existing management principles. He also emphasizes the importance of consistent lipid monitoring and clear communication across the various related specialties, including nutritionists, cardiologists, and lipid specialists.

Articles

Lipid management in 2025 has seen significant advancements with FDA approvals of inclisiran, plozasiran, and lerodalcibep-liga, alongside major trial results for olezarsen and enlicitide. These developments offer new preventive measures for ischemic stroke, hypercholesterolemia, and LDL-C management, particularly benefiting underserved populations. Key trials like CORALreef Lipids and VICTORION-Difference have demonstrated the efficacy of novel therapies in reducing LDL-C and triglycerides. Additionally, the REDUCE-IT trial highlighted icosapent ethyl's cardiovascular benefits, while obicetrapib showed robust LDL-C reductions in ASCVD patients.

Catch up on the most impactful headlines in dyslipidemia from all of 2025 with our Year in Review.

News

news page, resources on the topics of disease- and specialty-specific medical news and expert insight can be found. Content includes articles, interviews, videos, podcasts, and breaking news on health care research, treatment, and drug development.

Clinical

clinical page is a resource for content on every specialty, disease, and topic available on our medical news site.

Cardiology

Cardiology condition center page is a comprehensive resource for clinical news and insights on cardiovascular and cardiometabolic diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for heart disease and cardiovascular events, as well as associated diabetes, renal failure, and more...

Dyslipidemia

FDA News

Dyslipidemia in 2025: Year in Review

Image Credit: US Food and Drug Administration

Announced by parent company MannKind Corporation on December 23, 2025, the 

 has approved a supplemental New Drug Application (sNDA) for the furosemide On-body Infusor (FUROSCIX) to treat edema associated with 

 in pediatric patients weighing ≥43 kg.

“We are pleased to make FUROSCIX available to the pediatric population, a highly specific patient group, offering a convenient option outside the hospital setting for those who meet the weight criteria,” Ajay Ahuja, MD, MBA, chief medical officer of MannKind Corporation, said in a statement.

The FUROSCIX On-body Infusor was initially approved in 2022 for the treatment of edema in adults with chronic HF; later, in 2025, it received approval for adults with CKD as well. This third approval fulfills all post-marketing requirements outlined in the initial approval letter under the Pediatric Research Equity Act.

Furosemide’s initial approval was based on data from the phase 2 AT HOME-HF pilot study, a multicenter, randomized trial investigating subcutaneous furosemide 80 mg/10 mL versus standard of care in 51 patients with chronic HF and worsening congestion, uncontrolled by diuresis. The primary endpoint was a win ratio of a 30-day hierarchy composite of cardiovascular death, HF events, and change in N-terminal pro-B-type natriuretic peptide (NT-proBNP). Secondary endpoints included dyspnea severity, functional capacity, and quality of life.

Ultimately, 51 patients were enrolled and randomly assigned in a 2:1 ratio to either furosemide (n = 34) or standard of care (n = 17). Furosemide displayed greater reductions in body weight; between-group difference in least square mean change was -2.02 kg at day 3 (95% CI, -3.9 to -0.14; 

 = .035). Additionally, the furosemide-to-standard-of-care win ratio was 1.11 (95% CI, 0.48 to 2.5; 

 = .806). The most common adverse event with furosemide at the time was mild infusion site pain (11.8%).

In the same release, MannKind announced the FDA’s acceptance of a separate sNDA for the FUROSCIX ReadyFlow Autoinjector for adult patients with chronic HF or CKD. Unlike the On-body Infusor, the ReadyFlow is designed to deliver a subcutaneous furosemide injection in <10 seconds. If approved, the device could provide patients with a method of managing fluid buildup from home, eliminating the need for hospital admission.

“The FUROSCIX ReadyFlow Autoinjector marks a key milestone in expanding patient options and improving care,” Michael Castagna, PharmD, chief executive officer at MannKind Corporation, said in a separate statement regarding the acceptance. “By delivering treatment in under 10 seconds, the ReadyFlow Autoinjector has the potential to transform how adults with chronic heart failure or chronic kidney disease manage episodes of fluid buildup—providing faster relief, reducing hospital admissions, and lowering overall healthcare costs.”

The FUROSCIX ReadyFlow Autoinjector has been assigned a Prescription Drug User Fee Act (PDUFA) target action date of July 26, 2026.

MannKind Corporation. MannKind Shares FUROSCIX Business Updates. December 23, 2025. Accessed December 23, 2025. 

https://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-shares-furoscixr-business-updates

Konstam MA, Massaro J, Dhingra R, et al. Avoiding Treatment in Hospital With Subcutaneous Furosemide for Worsening Heart Failure: A Pilot Study (AT HOME-HF). JACC Heart Fail. 2024;12(11):1830-1841. 

MannKind Corporation. MannKind Announces U.S. FDA Accepts for Review its Supplemental New Drug Application (sNDA) of FUROSCIX ReadyFlow Autoinjector for the Treatment of Edema in Adults with Chronic Heart Failure or Chronic Kidney Disease. December 1, 2025. Accessed December 23, 2025. 

https://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-announces-us-fda-accepts-review-its-supplemental-new

The FDA has approved a supplemental New Drug Application for the FUROSCIX On-body Infusor to treat edema in pediatric patients with chronic heart failure and chronic kidney disease. Initially approved for adults, this marks the third approval for FUROSCIX, fulfilling Pediatric Research Equity Act requirements. The approval was based on the AT HOME-HF pilot study, which showed significant weight reduction in patients. Additionally, the FDA is reviewing the FUROSCIX ReadyFlow Autoinjector, designed for rapid subcutaneous furosemide delivery, with a decision expected by July 2026.

The FDA has approved an sNDA for the FUROSCIX On-body Infusor in pediatric patients and accepted another for the FUROSCIX ReadyFlow Autoinjector.

Heart Failure

The HCPLive heart failure page is a resource for medical news and expert insights on HF. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for heart disease, reduced and preserved ejection fraction, and more.

Nephrology

The HCPLive nephrology page is a resource for medical news and expert insights on kidney disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in nephrology, and more.

Chronic Kidney Disease

FDA Approves FUROSCIX On-Body Injector for Pediatric Patients, Accepts sNDA for ReadyFlow Autoinjector

Barriers to Using PCSK9-Targeting Therapies

The panelists address the real-world barriers that continue to limit the use of PCSK9-targeting therapies in ASCVD care. Despite strong evidence supporting their efficacy and safety, the experts note that cost, insurance restrictions, and prior authorization delays remain the most significant obstacles to access. Many patients who qualify under current guidelines face long approval processes or denials, leading to treatment gaps and frustration for both patients and clinicians. The panel also highlights the burden on healthcare teams, who spend substantial time navigating paperwork and appeals. Even when access is granted, lack of awareness or familiarity among some clinicians can delay therapy initiation. The experts emphasize that broader education, simplified approval pathways, and improved affordability are essential to expanding use. They conclude that overcoming these administrative and systemic hurdles is critical to ensuring more patients benefit from potent LDL-C–lowering therapies proven to reduce recurrent ASCVD events.

Videos

Explore the barriers to PCSK9 inhibitors, their underuse, and how addressing misconceptions can enhance patient outcomes in cholesterol management.

Video Series

Rethinking Prevention in ASCVD Through Cumulative LDL Exposure

The panelists revisit the concept of cumulative LDL-C exposure as a central driver of atherosclerotic risk, emphasizing that prevention must begin earlier and continue consistently throughout life. The experts explain that ASCVD develops over decades, with long-term exposure to elevated LDL-C creating a continuous burden on the vascular system. They discuss emerging data showing that earlier LDL-C lowering yields greater benefit than later intervention, even when the same LDL targets are eventually reached. This reinforces the principle that both the magnitude and duration of LDL-C reduction determine clinical outcomes. The panelists suggest that prevention frameworks should expand beyond “high-risk” patients to include younger adults with elevated LDL-C or familial predisposition, aiming to limit lifetime cholesterol exposure. They conclude that achieving and maintaining low LDL-C levels over time—rather than short-term correction—represents a paradigm shift in ASCVD prevention strategy and population health management.

Experts discuss evolving strategies in atherosclerosis prevention, emphasizing early intervention and the importance of cholesterol monitoring for better patient outcomes.

Abigail Brooks is an assistant managing editor for 

She joined MJH Life Sciences in August 2023 shortly after graduating from Monmouth University where she earned her BA in Communication with a concentration in Public Relations/Journalism and later an MA in Interactive Digital Media. She enjoys traveling, running, and reading books. She can be reached at abrooks@mjhlifesciences.com.

metabolic dysfunction-associated steatohepatitis (MASH)

 and the broader metabolic dysfunction-associated steatotic liver disease (MASLD) landscape, as the field moved decisively from first approvals toward therapeutic expansion and regulatory maturation. Momentum built on the foundation laid in 2024, with new data, evolving guidance, and growing confidence in noninvasive endpoints reshaping both drug development and clinical practice.

Resmetirom remained central to the year’s narrative as it reached the 1-year anniversary of its US Food and Drug Administration (FDA) approval and delivered compelling new data in compensated MASH cirrhosis, including marked reductions in liver stiffness. The FDA’s acceptance of FibroScan liver stiffness measurement as a reasonably likely surrogate endpoint further underscored a turning point for the field, signaling a pathway toward faster, more feasible clinical trials and broader therapeutic innovation.

At the same time, the MASH pipeline continued to diversify. Pemvidutide emerged as a standout with early histologic efficacy, meaningful weight loss, and sustained antifibrotic signals as it advanced toward phase 3 development, while efruxifermin offered longer-term hints of fibrosis benefit despite mixed primary results. The FDA approval of semaglutide for noncirrhotic MASH and subsequent American Association for the Study of Liver Diseases (AASLD) guidance updates reinforced the expanding role of metabolic therapies, collectively defining 2025 as a year of consolidation, acceleration, and clearer direction for MASH and MASLD care.

FDA Approves Semaglutide (Wegovy) Injection 2.4 mg for Noncirrhotic MASH

On August 15, 2025, the FDA approved Novo Nordisk’s semaglutide (Wegovy) injection 2.4 mg for the treatment of adults with MASH with moderate to advanced fibrosis, but not with cirrhosis, in conjunction with a reduced calorie diet and increased physical activity. The decision made semaglutide the second-ever FDA-approved MASH therapeutic and was based on results from the phase 3 ESSENCE trial investigating the effects of once-weekly semaglutide 2.4 mg injection on liver histology in adults with MASH and moderate to advanced liver fibrosis at week 72.

FDA Accepts FibroScan Letter of Intent for Surrogate Endpoint in MASH Trials

On September 8, 2025, the FDA’s Center for Drug Evaluation and Research, Office of New Drugs accepted Echosens’ Letter of Intent for the qualification of Liver Stiffness Measurement (LSM) by VCTE (FibroScan) as a reasonably likely surrogate endpoint in clinical trials for MASH. The decision marked the first time the FDA accepted the initiation of the qualification process of a noninvasive test as a reasonably likely surrogate endpoint in drug development for MASH. The Letter of Intent included official letters of support from Eli Lilly, Boehringer Ingelheim, and Novo Nordisk.

Resmetirom Reduces Liver Stiffness in Compensated MASH Cirrhosis

Positive 2-year results from the open-label compensated MASH cirrhosis (F4c) arm of the phase 3 MAESTRO-NAFLD-1 trial of Madrigal Pharmaceuticals’ resmetirom (Rezdiffra) show patients treated with resmetirom achieved marked reductions in liver stiffness, a surrogate for fibrosis, as measured by VCTE. The data represent the largest reduction in liver stiffness reported to date in an F4c MASH population.

Efruxifermin Shows Potential for Fibrosis Reduction in Phase 2b MASH Cirrhosis Trial

Efruxifermin, a bivalent fibroblast growth factor 21 (FGF21) analogue being developed for the treatment of MASH, failed to significantly reduce fibrosis without worsening of MASH at 36 weeks in a phase 2b trial. Despite missing the trial’s primary endpoint, the 50 mg dose of efruxifermin may have possible benefit on fibrosis reduction at 96 weeks. Notably, efruxifermin also appeared to be associated with improvements in MASH-related histologic findings, noninvasive markers of liver injury and fibrosis, and markers of glucose and lipid metabolism.

Pemvidutide Shows Significant MASH Effects, Weight Loss at 24 Weeks in Phase 2b IMPACT Trial

Positive topline results from the phase 2b IMPACT trial of Altimmune’s pemvidutide in patients with MASH show the trial met its primary endpoint, with statistically significant MASH resolution without worsening of fibrosis in up to 59.1% of participants and fibrosis improvement without worsening of MASH in up to 34.5% of participants in intent-to-treat analyses as well as weight loss of up to 6.2% at 24 weeks with no plateauing. The data made pemvidutide the first product candidate to demonstrate significant MASH effects and weight loss at 24 weeks.

AASLD Releases Updated Practice Guidance on Semaglutide (Wegovy) for MASH

In accordance with the addition of semaglutide to the MASH treatment landscape, the AASLD released an updated practice guidance on use of this therapy for MASH. The document serves as an update to the 2023 AASLD practice guidance on the clinical assessment and management of nonalcoholic fatty liver disease (NAFLD), now known as MASLD, and includes guidance on patient selection, safety considerations, treatment response, and concomitant therapy.

Pemvidutide Shows Continued Antifibrotic Activity for MASH, Progresses to Phase 3 Trial

Topline 48-week data from the phase 2b IMPACT trial of pemvidutide, a balanced 1:1 glucagon/GLP-1 dual receptor agonist, in patients with MASH showed treatment with pemvidutide achieved statistically significant improvements across treatment arms in key noninvasive tests, including ELF and LSM, versus placebo. Of note, these data exhibited continued reductions from week 24 and provide evidence of continued improvement in antifibrotic activity with both treatment doses.

Parent company Altimmune additionally announced that it held a productive End-of-Phase 2 meeting with the FDA resulting in alignment on the parameters for a registrational phase 3 trial of pemvidutide for MASH patients with moderate to advanced liver fibrosis.

Celebrating 1 Year of Resmetirom, Progress in MASH/MASLD

In honor of the 1 year anniversary of resmetirom’s FDA approval, a trio of expert hepatologists examined updates and unmet needs in the management of MASH and MASLD, highlighting resmetirom’s impact on disease management and looking ahead to what might be next in the pipeline.

Reflecting on Resmetirom’s Historic FDA Approval for MASH

Liver Lineup: GLP-1 RAs and FGF21s for MASH, with Mary Rinella, MD

Liver Lineup: Updates and Unfiltered Insights

, hosts Nancy Reau, MD, and Kimberly Brown, MD, sit down with Mary (Maru) Rinella, MD, to discuss the rapidly evolving therapeutic landscape for MASH, with a particular focus on GLP-1s and FGF21s in development.

Brooks A. FDA Approves Semaglutide (Wegovy) Injection 2.4 mg for Noncirrhotic MASH. HCPLive. August 15, 2025. Accessed December 22, 2025. 

https://www.hcplive.com/view/fda-approves-semaglutide-wegovy-injection-2-4-mg-for-noncirrhotic-mash

Brooks A. FDA Accepts FibroScan Letter of Intent for Surrogate Endpoint in MASH Trials. HCPLive. September 9, 2025. Accessed December 22, 2025. 

https://www.hcplive.com/view/fda-accepts-fibroscan-letter-of-intent-for-surrogate-endpoint-in-mash-trials

Brooks A. Resmetirom Reduces Liver Stiffness in Compensated MASH Cirrhosis. HCPLive. February 26, 2025. Accessed December 22, 2025. 

https://www.hcplive.com/view/resmetirom-reduces-liver-stiffness-compensated-mash-cirrhosis

Brooks A. Efruxifermin Shows Potential for Fibrosis Reduction in Phase 2b MASH Cirrhosis Trial. HCPLive. May 9, 2025. Accessed December 22, 2025. 

https://www.hcplive.com/view/exfruxifermin-misses-primary-endpoint-phase-2b-compensated-mash-cirrhosis-trial

Brooks A. Pemvidutide Shows Significant MASH Effects, Weight Loss at 24 Weeks in Phase 2b IMPACT Trial. HCPLive. June 26, 2025. Accessed December 22, 2025. 

https://www.hcplive.com/view/pemvidutide-shows-significant-mash-effects-weight-loss-24-weeks-phase-2b-impact-trial

Brooks A. AASLD Releases Updated Practice Guidance on Semaglutide (Wegovy) for MASH. HCPLive. November 7, 2025. Accessed December 22, 2025. 

https://www.hcplive.com/view/aasld-releases-updated-practice-guidance-semaglutide-wegovy-mash

Brooks A. Pemvidutide Shows Continued Antifibrotic Activity for MASH, Progresses to Phase 3 Trial. HCPLive. December 19, 2025. Accessed December 22, 2025. 

https://www.hcplive.com/view/pemvidutide-shows-continued-antifibrotic-activity-mash-progresses-to-phase-3-trial

Celebrating 1 Year of Resmetirom, Progress in MASH/MASLD. HCPLive. March 14, 2025. Accessed December 22, 2025. 

https://www.hcplive.com/special-report/celebrating-1-year-of-resmetirom-progress-in-mash-masld

Reau N, Brown KA, Rinella M. Liver Lineup: GLP-1 RAs and FGF21s for MASH, with Mary Rinella, MD. HCPLive. August 20, 2025. Accessed December 22, 2025. 

https://www.hcplive.com/view/liver-lineup-glp-1-ras-and-fgf21s-for-mash-with-mary-rinella-md

2025 was a transformative year for metabolic dysfunction-associated steatohepatitis (MASH) and metabolic dysfunction-associated steatotic liver disease (MASLD), marked by significant therapeutic advancements and regulatory progress. Resmetirom celebrated its first FDA approval anniversary, showing promising results in reducing liver stiffness. The FDA's acceptance of FibroScan as a surrogate endpoint facilitated faster clinical trials. Pemvidutide and efruxifermin showed potential in MASH treatment, while semaglutide received FDA approval for noncirrhotic MASH. Updated AASLD guidance further solidified the role of metabolic therapies in MASH management.

The MASH/MASLD year in review highlights FDA approvals, resmetirom data, semaglutide, pemvidutide, and advances in fibrosis and noninvasive endpoints in 2025.

Hepatology

MASH / MASLD

The HCPLive MASH & MASLD page is a comprehensive resource for clinical news and insights on metabolic dysfunction-associated steatotic liver disease and steatohepatitis. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for fatty liver disease, steatohepatitis, and more.

MASH/MASLD in 2025: Year in Review

Alex Hillenbrand is an assistant editor for 

. She earned her BA in English from Lafayette College in 2023 and went on to write for pop culture, entertainment, and sports media outlets before joining MJH Life Sciences in 2025. In her free time, Alex enjoys cooking, going on walks, and meeting new people. Contact her at mjhlifesciences.com.

Findings from a retrospective observational cohort study indicate podometrics may inform a less invasive treatment approach in IgA nephropathy (IgAN).


IgA Nephropathy

The HCPLive Berger disease page is a resource for medical news and expert insights on IgA nephropathy. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in Berger disease, and more.

Podometrics Could Guide IgAN Treatment While Reducing Invasiveness

Tim Smith joined the MJH Life Sciences team in 2022 and is currently an associate editor for HCPLive. He is also the executive producer of two podcasts: Skin of Color Savvy and The Medical Sisterhood. Previously, he was the producer of the Lungcast podcast. He graduated from UC Berkeley and worked in multimedia journalism as a staff writer prior to joining MJH. You can contact him at tsmith@mjhlifesciences.com.

To stay informed, catch up on some of the most notable alopecia areata news headlines from 2025 with our Year in Review.

Alopecia

Dermatology

The HCPLive dermatology page is a resource for medical news and expert insights on skin disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for dermatologic conditions, and more.

Alopecia in 2025: Year in Review

Sayna Norouzi, MD, is an assistant professor of medicine, clinical nephrologist, and founder and director of the glomerular disease and polycystic kidney disease clinics at Loma Linda University Medical Center.

In this segment, the panel discusses how monitoring strategies will need to adapt as B-cell–targeted therapies such as atacicept, sibeprenlimab, and povetacicept move into broader clinical use.

Monitoring Considerations with Emerging B-Cell Modulators in IgAN

In this segment, the panel reviews the emerging clinical data for two additional BAFF/APRIL–pathway inhibitors: sibeprenlimab and povetacicept. 

Additional Emerging BAFF and APRIL Inhibitors in IgAN

Chelsie Derman is an associate editor for 

who covers psychiatry, sleep medicine, geriatrics, migraine, and allergy. She joined MJH Life Sciences in September 2023 after graduating from The College of New Jersey with a bachelor’s degree in journalism and professional writing. In her free time, she enjoys creative writing and reading.

A study found that higher PM2.5 exposure during the first year after NICU discharge increased asthma risk in children with bronchopulmonary dysplasia by age 5.

Pulmonology

Infectious Disease condition center page is a comprehensive resource for clinical news and insights on respiratory health. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for asthma, COPD, interstitial lung disease, COVID-19, and more.

Asthma

The HCPLive asthma page is a comprehensive resource for clinical news and insights on asthmatic disease. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for allergic and severe asthma, and more.

Post-NICU PM2.5 Exposure Raises Asthma Risk in Children With Bronchopulmonary Dysplasia

Shervin Assassi, MD, is the director of the division of rheumatology at McGovern Medical School, UTHealth Houston.

Assassi reflects on the FDA approval of nerandomilast for progressive pulmonary fibrosis and the clinical benefits of the new PDE4B-targeted treatment option.

Pulmonary Fibrosis

Rheumatology

Rheumatology condition center page is a comprehensive resource for clinical news and insights on rheumatologic disease. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for arthritis, gout, nr-AxSpA, and more.

Nerandomilast Approval Expands Treatment Options for PPF, With Shervin Assassi, MD

Diana Isaacs, PharmD, is an endocrine clinical pharmacist, director of Education and Training in Diabetes Technology, and codirector of Endocrine Disorders in Pregnancy at the Cleveland Clinic.

Podcasts

Type 2 Diabetes

Obesity Management

Obesity Management condition center page, resources on the topics of medical news and expert insight into clinical weight management can be found. Content includes articles, interviews, videos, podcasts, and breaking news on obesity research, treatment, and drug development.

podcasts page features a feed of medical news and interview podcast series, including DocTalk, Lungcast, Derm Discussions, and Heart Trials.

Diabetes Dialogue

Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives is a monthly podcast hosted by Diana Isaacs, PharmD, and Natalie Bellini, DNP, aimed at providing a regular roundup of the latest clinically applicable insights across diabetes and metabolic diseases, with a focus on leveraging technology to improve care.

Diabetes Dialogue: Orforglipron, Cagrilintide, and the Libre Assist

The approval is based on the 64-week phase 3 OASIS 4 trial showing anaverage weight loss of ~17% if all patients stayed on treatment with semaglutide and ~14% regardless of if patients stayed on treatment.

FDA Approves Semaglutide (Wegovy) Pill As First Oral GLP-1 for Weight Loss

Innovative therapies and devices are transforming food allergy management, enhancing safety and quality of life for patients and families.

Food Allergy

Allergy

Allergy condition center page is a comprehensive resource for clinical news and insights on allergic and inflammatory diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for food and seasonal allergies, as well as allergic asthma and related conditions.

This Year In Medicine

A New Era in Food Allergy Treatment: The Push Toward Multi-Allergen Immunotherapy

Catch up on the most impactful headlines in ophthalmology from all of 2025 with our Year in Review.

Ophthalmology

Ophthalmology page, resources on the topics of medical news and expert insight into ophthalmic disease can be found. Content includes articles, interviews, videos, podcasts, and breaking news on eye disease research, treatment, and drug development.

Age-Related Macular Degeneration

age-related macular degeneration condition center page is a comprehensive resource for clinical news and insights on retina disease. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for patients with AMD.

Diabetic Macular Edema

The HCPLive diabetic macular edema page is a comprehensive resource for clinical news and insights on DME. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for the leading cause of blindness, and more.

Latest News

Dyslipidemia in 2025: Year in Review

FDA Approves FUROSCIX On-Body Injector for Pediatric Patients, Accepts sNDA for ReadyFlow Autoinjector

Barriers to Using PCSK9-Targeting Therapies

Rethinking Prevention in ASCVD Through Cumulative LDL Exposure

MASH/MASLD in 2025: Year in Review